syptoms. Stigma and social isolation T-scores were above the general population average (T-score=50) in 69 (58.5%) and 57 (48.3%) participants, respectively. Higher levels of both stigma and social isolation correlated with more severe depression (t=0.527, p<0.0001 and t=0.551, p<0.0001, respectively). Social isolation correlated with stigma (t=0.945, p<0.0001) and the effect of stigma on depression was no longer significant (t=−0.018, p=0.88) after we examined the mediator effect of social isolation and controlled for sociodemographics (table 1, Model 1). Lower education (high school vs some college or higher) significantly increased the strength of correlation between stigma and depression after controlling for sociodemographics (table 1, Model 2). Poverty and African American race also increased the strength of the relationship but were not significant.

Conclusions Nearly a third with CCLE reported moderate to severe depressive symptoms. Social stigma contributed to depression through feelings of social isolation, and those with lower education were more vulnerable to the impact of stigma on depression. Clinical and public health programs should help strengthen social connections in people with CCLE and reduce stigmatization in the community, particularly among those from socioeconomically disadvantaged groups.

Funding Source(s): Centers for Disease Control and Prevention (CDC) grant U01DP005119.

243 VALIDATION OF PEDANAM AS AN INSTRUMENT OF COGNITIVE EVALUATION IN NEUROPSYCHIATRIC SLE

1Jaqueline de Amorim*, 2Simone Kishimoto, 3Paula Fernandes, 4Clovis Silva, 3Roberto Mairini, 5Simone Appenzeller, 1Child and Adolescente graduate program UNICAMP; 2Physiopathology graduate program; 3UNICAMP; 4Instituto da Criança USP; 5University of Campinas

Background Translation, validation, and use of a computerized battery for cognitive evaluation of patients with systemic lupus erythematosus (SLE) as part of an investigation of neuropsychiatric manifestations is useful and allows multicenter studies.

Methods This is a quantitative transversal study with control group conducted in pediatric and adult rheumatology clinics. The computer test batteries ANAM (Automated Neuropsychological Assessment Metrics) or PedAnam (PediAnam version) was submitted to the Guidelines for the Process of Cross-Cultural Adaptation. This process has five stages: Initial translation, synthesis of the translations, back translation, harmonization, test of the prefinal version and final version. After the process, we apply the ANAM in 98 SLE patients and healthy age-matched individuals. All individuals underwent an evaluation through the battery tests taking 30 min on average to solve the problems.

Results 98 SLE patients, 69 female and 29 male, ages between 6 and 68 years with mean of 28.6. The control group had 84 people, 73 female and 11 male, ages between 6 and 63 years with mean of 25. For the evaluation was used the Performance Validity Index score, that provides a performance indicator, between 0 and 14, for someone with good effort, or above for someone outside the range of that expected for someone providing good effort. Patients presented an average performance of 8.05, with a minimum of 0 and a maximum of 33, while the control group had a mean of 4.4, minimum 0 and maximum of 27. As the smaller score results in a better effort, it is possible to notice meaningful differences between the groups (p<0.05).

Conclusions Cognitive difficulties are often observed in SLE and practical tools like ANAM and PedAnam should be used to measure the cognitive loss that patients may have; these losses should be monitored more closely if there are other neuropsychiatric symptoms.

Funding Source(s): CNPq

CAPES

FAPESP

244 POLYMORPHISM OF MICRONRNA REGION IN THE TNFA GENE IN CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS

1Jessica Vivaldo*, 1Mariana Postal, 1Nailu Sinicato, 1Roberto Marini, 2Timothy Niewold, 3Simone Appenzeller. 1UNICAMP; 2NYU; 3University of Campinas

Background Studies have implicated microRNAs (miRNAs) in the pathogenesis of systemic lupus erythematosus (SLE). miRNAs regulate approximately 90% of the protein-encoding genes and play a central role in various biological processes, including impairment of cell differentiation and proliferation and apoptosis. Polymorphism in miRNA regions of TNFA gene may account for the variations observed in the clinical. The aim of this study was to investigate the presence of polymorphisms of miRNA regions of TNFA gene associated to clinical and laboratory profile of these SLE patients.

Methods Consecutive childhood-onset SLE (cSLE) patients followed at Pediatric Rheumatology Unit of the Unicamp were enrolled in study. Healthy volunteers with were included as control group. A complete clinical, laboratory and neurological was performed in all subjects. cSLE patients were further assessed for clinical and laboratory SLE manifestations, disease activity [SLE Disease Activity Index (SLEDAI)], damage [Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)] and current therapy. Total dose of corticosteroids and other immunosuppressant medications used since the onset of disease were calculated by data obtained by careful review of the medical charts. We investigated miRNA region of the TNFA gene in cSLE compared to healthy volunteers using DNA Sequencing by Capillary Electrophoresis. Data were compared by non-parametric tests.

Results We included 110 cSLE patients [83 women (75.4%)]. The mean disease duration was 13.18±4.32 (0.09–20 years). We included as a control group 60 healthy individuals [52 women (86.7%)] recruited from the local community. The mean score of cumulative SLEDAI was 2.93±2.20 (0.09–12.52). The mean of total corticosteroid dose was 2343.54±1665.55 mg. We identified polymorphism rs3093665 (c.*77 A>C) in 8 (7.3%) cSLE patients, polymorphism rs3093666 (c.*419 C>T) in 3 (2.7%) patients and polymorphism rs3093667 (c.*453 G>T) in 2 (1.8%) cSLE patients. Polymorphism rs3093665 is located in a region of interest, into a miRNA region-binding site of miR-452 and polymorphism rs3093667 into a miRNA